Antiepileptic drug treatment in children

References

• Kwan P, Brodie MJ. Refractory epilepsy: mechanisms and solutions. Expert Rev. Neurother.6, 397–406 (2006).
   PubMedGoogle Scholar
• Pellock JM, Watemberg N. New antiepileptic drugs in children: present and future. Semin. Pediatr. Neurol.4, 9–18(1997).
   PubMedGoogle Scholar
• French JA, Kanner AM, Bautista J et al. American Academy of Neurology Therapeutics and Technology Assessment Subcommittee; American Academy of Neurology Quality Standards Subcommittee; American Epilepsy Society Therapeutics and Technology Assessment Subcommittee; American Epilepsy Society Quality Standards Subcommittee. Efficacy and tolerability of the new antiepileptic drugs I: treatment of new onset epilepsy. Neurology62, 1252–1260 (2004).
   PubMed Web of Science ®Google Scholar
• Bourgeois BF. Childhood epilepsy: pharmacological considerations. Acta Neurol. Scand. Suppl.140, 23–27 (1992).
   PubMedGoogle Scholar
• Bryant A, Dreifuss FE. Valproic acid hepatic fatalities. III. U.S. experience since 1986. Neurology46, 465–469 (1996).
   PubMed Web of Science ®Google Scholar
• Messenheimer JA, Guberman AH. Rash with lamotrigine: dosing guidelines. Epilepsia41, 488 (2000).
   PubMedGoogle Scholar
• Asconape JJ, Penry JK, Dreifuss FE, Riela A, Mirza W. Valproate-associated pancreatitis. Epilepsia34, 177–183 (1993).
   PubMed Web of Science ®Google Scholar
• Bourgeois BF. Determining the effects of antiepileptic drugs on cognitive function in pediatric patients with epilepsy. J. Child Neurol.19(Suppl. 1), S15–S24 (2004).
   Google Scholar
• Sazgar M, Bourgeois BF. Aggravation of epilepsy by antiepileptic drugs. Pediatr. Neurol.33, 227–234 (2005).
   PubMedGoogle Scholar
• Somerville ER. Aggravation of partial seizures by antiepileptic drugs: is there evidence from clinical trials? Neurology59, 79–83 (2002).
   PubMedGoogle Scholar
• Genton P, Gelisse P, Thomas P, Dravet C. Do carbamazepine and phenytoin aggravate juvenile myoclonic epilepsy? Neurology55, 1106–1109 (2000).
   PubMed Web of Science ®Google Scholar
• Carrazana EJ, Wheeler SD. Exacerbation of juvenile myoclonic epilepsy with lamotrigine. Neurology56, 1424–1425 (2001).
   PubMed Web of Science ®Google Scholar
• Biraben A, Allain H, Scarabin JM, Schuck S, Edan G. Exacerbation of juvenile myoclonic epilepsy with lamotrigine. Neurology55(11), 1758 (2000).
   PubMed Web of Science ®Google Scholar
• Bourgeois BF. Reducing overtreatment. Epilepsy Res.52, 53–60 (2002).
   PubMedGoogle Scholar
• Bourgeois BF. New antiepileptic drugs in children: which ones for which seizures? Clin. Neuropharmacol.23, 119–132 (2000).
   PubMed Web of Science ®Google Scholar
• Meldrum BS. Update on the mechanism of action of antiepileptic drugs. Epilepsia37(Suppl. 6), S4–S11 (1996).
   PubMedGoogle Scholar
• Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. Lancet Neurol.2, 347–356 (2003).
   PubMed Web of Science ®Google Scholar
• Marson AG, Kadir ZA, Hutton JL, Chadwick DW. The new antiepileptic drugs: a systematic review of their efficacy and tolerability. Epilepsia38, 859–880 (1997).
   PubMed Web of Science ®Google Scholar
• Bourgeois BF. New antiepileptic drugs. Curr. Opin. Pediatr.8, 543–548 (1996).
   PubMedGoogle Scholar
• Farwell JR, Lee YJ, Hirtz DG et al. Phenobarbital for febrile seizures – effects on intelligence and on seizure recurrence. N. Engl. J. Med.322, 364–369 (1990).
   PubMed Web of Science ®Google Scholar
• Riva D, Devoti M. Discontinuation of phenobarbital in children: effects on neurocognitive behavior. Pediatr. Neurol.14, 36–40 (1996).
   PubMedGoogle Scholar
• Camfield CS, Chaplin S, Doyle AB et al. Side effects of phenobarbital in toddlers: behavioral and cognitive aspects. J. Pediatr.95, 361–365 (1979).
   PubMedGoogle Scholar
• Hahn TJ. Serum 25-hydroxycalciferol levels and bone mass in children on chronic anticonvulsant therapy. N. Engl. J. Med.292, 550 (1975).
   Web of Science ®Google Scholar
• Greenlaw R. Osteomalacia (OM) from anticonvulsant (ACV) drugs: therapeutic implications. Clin. Res.20, 427 (1972).
   Google Scholar
• Kilarski DJ, Buchanan C, Behren LV. Soft-tissue damage associated with intravenous phenytoin. N. Engl. J. Med.311, 1186–1187 (1984).
   PubMedGoogle Scholar
• Leppik IE, Boucher BA, Wilder BJ et al. Pharmacokinetics and safety of a phenytoin prodrug given IV or IM in patients. Neurology40, 456–460 (1990).
   PubMed Web of Science ®Google Scholar
• Johannessen SI. Laboratory monitoring of antiepileptic drugs. In: Antiepileptic Drugs (4th Edition). Levy RH, Mattson RH, Meldrum BS (Eds). Raven Press, NY, USA, 179–187 (1995).
   Google Scholar
• Yaari Y, Selzer ME, Pincus JH. Phenytoin: mechanisms of its anticonvulsant action. Ann. Neurol.20, 171–184 (1986).
   PubMed Web of Science ®Google Scholar
• Anast CS. Anticonvulsant drugs and calcium metabolism. N. Engl. J. Med.292, 587 (1975).
   Google Scholar
• Rating D, Wolf C, Bast T. Sulthiame as monotherapy in children with benign childhood epilepsy with centrotemporal spikes: a 6-month randomized, double-blind, placebo-controlled study. Sulthiame Study Group. Epilepsia41(10), 1284–1288 (2000).
   PubMedGoogle Scholar
• Wirrell E, Ho AW, Hamiwka L. Sulthiame therapy for continuous spike and wave in slow-wave sleep. Pediatr. Neurol.35, 204–208 (2006).
   PubMedGoogle Scholar
• Ben-Zeev B, Watemberg N, Lerman P, Barash I, Brand N, Lerman-Sagie T. Sulthiame in childhood epilepsy. Pediatr. Int.46, 521–524 (2004).
   PubMed Web of Science ®Google Scholar
• Lerman P, Lerman-Sagie T. Sulthiame revisited. J. Child Neurol.10, 241 (1995).
   PubMedGoogle Scholar
• Panayiotopoulos CP. Treatment of typical absence seizures and related epileptic syndromes. Peadiatr. Drugs3, 379–403 (2001).
   PubMedGoogle Scholar
• Wallace SJ. Myoclonus and epilepsy in childhood: a review of treatment with valporate, ethosuximide, lamotrigine and zonisamide. Epilepsy Res.29, 147–154 (1998).
   PubMed Web of Science ®Google Scholar
• Snead OC 3rd, Hosey LC. Treatment of epileptic falling spells with ethosuximide. Brain Dev.9, 602–604 (1987).
   PubMedGoogle Scholar
• Oguni H, Uehara T, Tanaka T, Sunahara M, Hara M, Osawa M. Dramatic effect of ethosuximide on epileptic negative myoclonus: implications for the neurophysiological mechanism. Neuropediatrics29, 29–34 (1998).
   PubMedGoogle Scholar
• Hvidberg EF, Dam M. Clinical pharmacokinetics of anticonvulsants. Clin. Pharmacokinet.1, 161 (1976).
   PubMedGoogle Scholar
• Mattson RH, Cramer JA. Valproic acid and ethosuximide interaction. Ann. Neurol.7, 583–584 (1980).
   PubMed Web of Science ®Google Scholar
• Bourgeois BF. Felbamate. Semin. Pediatr. Neurol.4, 3–8 (1997).
   PubMedGoogle Scholar
• Rho JM, Donevan DS, Rogawski MA. Mechanism of action of the anticonvulsant felbamate: opposing effects on N-methyl-D-aspartate and γ-aminobutyric acid A receptors. Ann. Neurol.35, 229–234 (1994).
   PubMed Web of Science ®Google Scholar
• Leppik IE, Graves N, Devinsky O. New antiepileptic medications. Neurol. Clin.11, 923–950 (1993).
   PubMedGoogle Scholar
• Burdette DE, Zheng C, Tornow MA et al. Felbamate reduces atypical generalized spike wave discharges in patients with Lennox–Gastaut syndrome. Neurology42(Suppl. 3), 330 (1992).
   Google Scholar
• Kelley MT, Walson PD, Cox S, Dusci LJ. Population pharmacokinetics of felbamate in children.Ther. Drug Monit.19(1), 29–36 (1997).
   PubMedGoogle Scholar
• Pellock JM. Felbamate in epilepsy therapy. Evaluating the risks. Drug Saf.21, 225–239 (1999).
   PubMed Web of Science ®Google Scholar
• Anon. Recommendation for the immediate withdrawal of patients from treatment with Felbatol(R) (felbamate). FDA Medical Bulletin24(No. 2), 5 (1994).
   Google Scholar
• Pellock JM, Brodie MJ. Felbamate: update. Epilepsia38(12), 1261–1264 (1997).
   PubMed Web of Science ®Google Scholar
• Chadwick DW, Anhut H, Greiner MJ et al. A double-blind trial of gabapentin monotherapy for newly diagnosed partial seizures. International Gabapentin Monotherapy Study Group 945–977. Neurology51, 1282–1288 (1998).
   PubMed Web of Science ®Google Scholar
• Trudeau V, Myers S, LaMoreaux L, Anhut H, Garofalo E, Ebersole J. Gabapentin in naive childhood absence epilepsy: results from two double-blind, placebo-controlled, multicenter studies. J. Child Neurol.11, 470–475 (1996).
   PubMed Web of Science ®Google Scholar
• Bourgeois B, Brown LW, Pellock JMet al. Gabapentin (Neurontin®) monotherapy in children with benign childhood epilepsy with centrotemporal spikes (BECTS): a 36-week, double-blind, placebo-controlled study [abstract]. Epilepsia39(Suppl. 6), 163 (1998) (Abstract 5.067).
   Google Scholar
• Andrews CO, Fischer JH. Gabapentin: a new agent for the management of epilepsy. Ann. Pharmacother.28(10), 1188–1196 (1994).
   PubMed Web of Science ®Google Scholar
• Tatum WO 4th, Zachariah SB. Gabapentin treatment of seizures in acute intermittent porphyria. Neurology45, 1216–1217 (1995).
   PubMed Web of Science ®Google Scholar
• Barron TF, Hunt SL, Hoban TF, Price ML. Lamotrigine monotherapy in children. Pediatr. Notrieurol.23, 160–163 (2000).
   PubMed Web of Science ®Google Scholar
• Culy CR, Goa KL. Lamotriginre. A review of its use in childhood epilepsy. Pediatr. Drugs2, 299–330 (2000).
   PubMedGoogle Scholar
• Motte J, Trevathan E, Arvidsson JF, Barrera MN, Mullens EL, Manasco P. Lamotrigine for generalized seizures associated with the Lennox–Gastaut syndrome. Lamictal Lennox–Gastaut Study Group. N. Engl. J. Med.337(25), 1807–1812 (1997).
   PubMed Web of Science ®Google Scholar
• Frank LM, Enlow T, Holmes GL et al. Lamictal (lamotrigine) monotherapy for typical absence seizures in children. Epilepsia40, 973–979 (1999).
   PubMed Web of Science ®Google Scholar
• Coppola G, Auricchio G, Federico R, Carotenuto M, Pascotto A. Lamotrigine versus valproic acid as first-line monotherapy in newly diagnosed typical absence seizures: an open-label, randomized, parallel-group study. Epilepsia45, 1049–1053 (2004).
   PubMedGoogle Scholar
• Biton V, Sackellares JC, Vuong A, Hammer AE, Barrett PS, Messenheimer JA. Double-blind, placebo-controlled study of lamotrigine in primary generalized tonic-clonic seizures. Neurology65(11), 1737–1743 (2005).
   PubMed Web of Science ®Google Scholar
• Guberman AH, Besag FMC, Brodie MJ et al. Lamotrigine-associated rash: risk/benefit considerations in adults and children. Epilepsia40, 985–991 (1999).
   PubMed Web of Science ®Google Scholar
• Wong IC, Mawer GE, Sander JW. Factors influencing the incidence of lamotrigine-related skin rash. Ann. Pharmacother.33(10), 1037–1042 (1999).
   PubMedGoogle Scholar
• Brodie MJ, Richens A, Yuen AW. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Lancet345, 476–479 (1995).
   PubMed Web of Science ®Google Scholar
• Glauser TA, Clark PO, Strawsburg R. A pilot study of topiramate in the treatment of infantile spasms. Epilepsia39(12), 1324–1328.
   PubMedGoogle Scholar
• Biton V, Bourgeois BF; YTC/YTCE Study Investigators. Topiramate in patients with juvenile myoclonic epilepsy. Arch. Neurol.62, 1705–1708 (2005)
   PubMedGoogle Scholar
• Takeoka M, Holmes GL, Thiele E et al. Topiramate and metabolic acidosis in pediatric epilepsy. Epilepsia42, 387–392 (1998).
   Google Scholar
• Philippi H, Boor R, Reitter B. Topiramate and metabolic acidosis in infants and toddlers. Epilepsia43, 744–777 (2002).
   PubMed Web of Science ®Google Scholar
• Arcas J, Ferrer T, Roche MC, Martinez-Bermejo A, Lopez-Martin V. Hypohidrosis related to the administration of topiramate to children. Epilepsia42(10), 1363–1365 (2001).
   PubMed Web of Science ®Google Scholar
• Meldrum BS, Chapman AG. Basic mechanisms of Gabitril (tiagabine) and future potential developments. Epilepsia40(Suppl. 9), S2–S6 (1999).
   PubMedGoogle Scholar
• Perucca E. The clinical pharmacokinetics of the new antiepileptic drugs. Epilepsia40(Suppl. 9), S7–S13 (1999).
   PubMed Web of Science ®Google Scholar
• Schapel G, Chadwick D. Tiagabine and non-convulsive status epilepticus. Seizure5, 153–156 (1996).
   PubMed Web of Science ®Google Scholar
• Ettinger AB, Bernal OG, Andriola MR et al. Two cases of nonconvulsive status epilepticus in association with tiagabine therapy. Epilepsia40, 1159–1162 (1999).
   PubMed Web of Science ®Google Scholar
• Mackay M, Weiss S, Snead OC 3rd. Treatment of infantile spasms: an evidence-based approach. Int. Rev. Neurobiol.49, 157–184 (2002).
   PubMed Web of Science ®Google Scholar
• Buncic JR, Westall CA, Panton CM, Munn JR, MacKeen LD, Logan WJ. Characteristic retinal atrophy with secondary "inverse" optic atrophy identifies vigabatrin toxicity in children. Ophthalmology111(10), 1935–1942 (2004).
   PubMed Web of Science ®Google Scholar
• Rigolet MH, Baulac M, Nordmann JP. Electrophysiological monitoring of epileptic patients treated with vigabatrin. J. Fr. Ophtalmol.28, 635–641 (2005).
   PubMedGoogle Scholar
• Miller NR. Using the electroretinogram to detect and monitor the retinal toxicity of anticonvulsants. Neurology55(3), 333–334 (2000).
   PubMedGoogle Scholar
• Gallagher MJ, Eisenman LN, Brown KM et al. Levetiracetam reduces spike-wave density and duration during continuous EEG monitoring in patients with idiopathic generalized epilepsy. Epilepsia45, 90–91 (2004).
   PubMedGoogle Scholar
• Krauss GL, Betts T, Abou-Khalil B, Gergey G, Yarrow H, Miller A. Levetiracetam treatment of idiopathic generalised epilepsy. Seizure12, 617–620 (2003).
   PubMed Web of Science ®Google Scholar
• Cavitt J, Privitera M. Levetiracetam induces a rapid and sustained reduction of generalized spike-wave and clinical absence. Arch. Neurol.61(10), 1604–1607 (2004).
   PubMedGoogle Scholar
• Patsalos PN. Properties of antiepileptic drugs in the treatment of idiopathic generalized epilepsies. Epilepsia46(Suppl. 9), 140–148 (2005).
   PubMed Web of Science ®Google Scholar
• Patsalos PN. Clinical pharmacokinetics of levetiracetam. Clin. Pharmacokinet.43(11), 707–724 (2004).
   PubMed Web of Science ®Google Scholar
• Vigevano F. Levetiracetam in pediatrics. J. Child Neurol.20, 87–93 (2005).
   PubMed Web of Science ®Google Scholar
• Bill PA, Vigonius U, Pohlmann H et al. A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in adults with previously untreated epilepsy. Epilepsy Res.27, 195–204 (1997).
   PubMed Web of Science ®Google Scholar
• Christe W, Kramer G, Vigonius U et al. A double-blind controlled clinical trial: oxcarbazepine versus sodium valproate in adults with newly diagnosed epilepsy. Epilepsy Res.26, 451–460 (1997).
   PubMed Web of Science ®Google Scholar
• Dam M, Ekberg R, Loyning Y, Waltimo O, Jakobsen K. A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy. Epilepsy Res.3, 70–76 (1989).
   PubMed Web of Science ®Google Scholar
• Tecoma ES. Oxcarbazepine. Epilepsia40(Suppl. 5), S37–S46 (1999).
   PubMedGoogle Scholar
• Bourgeois BF, D’Souza J. Long-term safety and tolerability of oxcarbazepine in children: a review of clinical experience. Epilepsy Behav.7, 375–382 (2005).
   PubMedGoogle Scholar
• Sakamoto K, Kurokawa T, Tomita Set al. Effects of zonisamide on children with epilepsy. Curr. Therapeut. Res.13, 378–383 (1988).
   Google Scholar
• Glauser TA, Pellock JM. Zonisamide in pediatric epilepsy: review of the Japanese experience. J. Child Neurol.17, 87–96 (2002).
   PubMed Web of Science ®Google Scholar
• Bourgeois BF. Pharmacokinetic properties of current antiepileptic drugs: what improvements are needed? Neurology55(Suppl. 3), S11–S16 (2000).
   Google Scholar
• Low PA, James S, Peschel T, Leong R, Rothstein A. Zonisamide and associated oligohidrosis and hyperthermia. Epilepsy Res.62, 27–34 (2004).
   PubMed Web of Science ®Google Scholar
• Arroyo S, Anhut H, Kugler AR et al. Pregabalin add-on treatment: a randomized, double-blind, placebo-controlled, dose-response study in adults with partial seizures. Epilepsia45, 20–27 (2004).
   PubMed Web of Science ®Google Scholar
• Huppertz HJ, Feuerstein TJ, Schulze-Bonhage A. Myoclonus in epilepsy patients with anticonvulsive add-on therapy with pregabalin. Epilepsia42, 790–792 (2001).
   PubMed Web of Science ®Google Scholar
• Ben-Menachem E. Pregabalin pharmacology and its relevance to clinical practice. Epilepsia45(Suppl. 6), 13–18 (2004).
   PubMed Web of Science ®Google Scholar
• Brodie MJ, French JA. Role of levetiracetam in the treatment of epilepsy. Epileptic Disord.5(Suppl. 1), S65–S72 (2003).
   Google Scholar
• Morrell MJ. Antiepileptic medications for the treatment of epilepsy. Semin. Neurol.22, 247–258 (2002).
   PubMedGoogle Scholar
• Bourgeois BF. Chronic management of seizures in the syndromes of idiopathic generalized epilepsy. Epilepsia44(Suppl. 2), 27–32 (2003).
   PubMedGoogle Scholar
• Sato S, White BG, Penry JK, Dreifuss FE, Sackellares JC, Kupferberg HJ. Valproic acid versus ethosuximide in the treatment of absence seizures. Neurology32, 157–163 (1982).
   PubMed Web of Science ®Google Scholar
• Callaghan N, O’Hare J, O’Driscoll D, O’Neill B, Daly M. Comparative study of ethosuximide and sodium valproate in the treatment of typical absence seizures (petit mal). Dev. Med. Child Neurol.24, 830–836 (1982).
   PubMed Web of Science ®Google Scholar
• Villarreal HJ, Wilder BJ, Willmore LJ, Bauman AW, Hammond EJ, Bruni J. Effect of valproic acid on spike and wave discharges in patients with absence seizures. Neurology28, 886–891 (1978).
   PubMed Web of Science ®Google Scholar
• Vinten J, Adab N, Kini U, Gorry J, Gregg J, Baker GA Liverpool and Manchester Neurodevelopment Study Group. Neuropsychological effects of exposure to anticonvulsant medicationin utero. Neurology64, 949–954 (2005).
   PubMed Web of Science ®Google Scholar
• Astradsson A, Olafsson E, Ludvigssion P et al. Icelandic epilepsy: an incidence study in Iceland. Epilepsia39, 884–886 (1998).
   PubMedGoogle Scholar
• Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia30, 389–399 (1989).
   PubMed Web of Science ®Google Scholar
• Nicolai J, Aldenkamp AP, Arends J, Weber JW, Vles JS. Cognitive and behavioral effects of nocturnal epileptiform discharges in children with benign childhood epilepsy with centrotemporal spikes. Epilepsy Behav.8, 56–70 (2006).
   PubMed Web of Science ®Google Scholar
• Tzitiridou M, Panou T, Ramantani G, Kambas A, Spyroglou K, Panteliadis C. Oxcarbazepine monotherapy in benign childhood epilepsy with centrotemporal spikes: a clinical and cognitive evaluation. Epilepsy Behav.7, 458–467 (2005).
   PubMed Web of Science ®Google Scholar
• Mitsudome A, Ohfu M, Yasumoto S et al. The effectiveness of clonazepam on the Rolandic discharges. Brain Dev.19, 274–278 (1997).
   PubMedGoogle Scholar
• Bast T, Volp A, Wolf C, Rating D. Sulthiame Study Group. The influence of sulthiame on EEG in children with benign childhood epilepsy with centrotemporal spikes (BECTS). Epilepsia44, 215–220 (2003).
   PubMedGoogle Scholar
• Mackay MT, Weiss SK, Adams-Webber T et al. American Academy of Neurology; Child Neurology Society. Practice parameter: medical treatment of infantile spasms: report of the American Academy of Neurology and the Child Neurology Society. Neurology62(10), 1668–1681 (2004).
   PubMed Web of Science ®Google Scholar
• French JA, Kanner AM, Bautista J, Abou-Khalil Bet al. American Academy of Neurology Therapeutics and Technology Assessment Subcommittee; American Academy of Neurology Quality Standards Subcommittee; American Epilepsy Society Therapeutics and Technology Assessment Subcommittee; American Epilepsy Society Quality Standards Subcommittee. Efficacy and tolerability of the new antiepileptic drugs, II: treatment of refractory epilepsy: report of the TTA and QSS Subcommittees of the American Academy of Neurology and the American Epilepsy Society. Epilepsia45, 410–423 (2004).
   PubMedGoogle Scholar
• Tassinari CA, Dravet C, Roger J, Cano JP, Gastaut H. Tonic status epilepticus precipitated by intravenous benzodiazepine in five patients with Lennox–Gastaut syndrome. Epilepsia13, 421–435 (1972).
   PubMed Web of Science ®Google Scholar
• DiMario FJ Jr, Clancy RR. Paradoxical precipitation of tonic seizures by lorazepam in a child with atypical absence seizures. Pediatr. Neurol.4, 249–251 (1988).
   PubMed Web of Science ®Google Scholar
• Horn CS, Ater SB, Hurst DL. Carbamazepine-exacerbated epilepsy in children and adolescents. Pediatr. Neurol.2, 340–345 (1986).
   PubMedGoogle Scholar
• Glauser T, Gerhard Kluger, Rajesh Sachedo et al. Efficacy and safety of rufinamide adjunctive therapy in patients with Lennox–Gastaut syndrome (LGS): a multicenter, randomized, double-blind, placebo-controlled, parallel trial: LBS.001 Neurology64, 1826–1988 (2005).
   Web of Science ®Google Scholar
• Frost M, Gates J, Helmers SL, Wheless JW et al. Vagus nerve stimulation in children with refractory seizures associated with Lennox–Gastaut syndrome. Epilepsia42, 1148–1152 (2001).
   PubMed Web of Science ®Google Scholar
• Painter MJ, Scher MS, Stein AD et al. Phenobarbital compared with phenytoin for the treatment of neonatal seizures. N. Engl. J. Med.341, 485–489 (1999).
   PubMed Web of Science ®Google Scholar